Multiple sclerosis: dimethyl fumarate and fingolimod - from clinical trials to clinical practice

Abstract

Multiple sclerosis (MS) is the most common autoimmune disorder affecting the central nervous system. It is the most commoncause of neurologic disability in young and middle-aged adults also.

To minimize the clinical burden associated with MS, earlycontrol of CNS disease activity is a treatment priority. Dimethyl fumarate (DMF) and fingolimod are important drugs in the arsenalfor treating relaps/remitent type of MS.

This article is concerned with the DMF and fingolimod in clinical trials and clinical practice.

Keywords

• multiple sclerosis
• dimethyl fumarate
• fingolimod